Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A231701CD||Alliance||Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention||Cancer Prevention and Control CIRB||Available to Open|
|A071801||Alliance||Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA1183||ECOG-ACRIN||FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE||Adult CIRB - Late Phase Emphasis||Available to Open|
|AOST1521||COG||A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate; CDX-011 (Glembatumumab Vedotin; CR011-vcMMAE; IND# 128248; NSC# 763737); in Recurrent or Refractory Osteosarcoma||Pediatric CIRB||Available to Open|
|EA8153||ECOG-ACRIN||Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|ARET0332||COG||A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|EA9152||ECOG-ACRIN||A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1318||SWOG||A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone; Vincristine; Methotrexate; 6-Mercaptopurine) for Patients >= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517); Prednisone and Blinatumomab for Patients >= 65 Years Of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL; and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF)||Adult CIRB - Early Phase Emphasis||Available to Open|
|A221602||Alliance||Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial||Cancer Prevention and Control CIRB||Available to Open|
|GOG-0252||GOG||A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian; Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865; IND #113912)||Adult CIRB - Late Phase Emphasis||Available to Open|